Ascletis Unveils New Anti-Obesity Therapies at ObesityWeek® 2026

Ascletis Unveils New Anti-Obesity Therapies at ObesityWeek® 2026



At the recently held ObesityWeek® 2026 in Washington, D.C., Ascletis Pharma Inc. (HKEX: 1672) presented groundbreaking preclinical data regarding their new candidates targeting obesity treatment. The company highlighted two promising therapies: the oral small molecule GIPR agonist ASC48 and the GLP-1R/GIPR dual-targeted oral small molecule ASC30_48 FDC, as well as the long-acting injectable GLP-1R/GIPR/GCGR triple peptide agonist ASC37.

Key Findings from the Study



ASC30_48 FDC: A Potential Game-Changer


One of the highlights of the conference was the introduction of ASC30_48 FDC, which is a first-of-its-kind oral dual fixed-dose combination that targets both GLP-1R and GIPR receptors. In a preclinical study conducted on non-human primates, the ASC30_48 FDC demonstrated an impressive 52% relative improvement in weight loss compared to the monotherapy ASC30. The outcome revealed a weight reduction of 10.5% with ASC30_48 FDC versus 6.9% with ASC30 alone, successfully showcasing the added efficacy of the combination treatment.

ASC37: Long-Acting Injectable Solution


In addition, the clinical data presented for ASC37 illustrated its long-acting potential for chronic weight management with a subcutaneous administration schedule varying from once a month to once every quarter. Powered by Ascletis’ proprietary technologies—Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP)—ASC37 exhibited a remarkable half-life of 372 hours, significantly outperforming the previously available treatments like retatrutide.

In Vitro Results


The in vitro assessments of ASC48 demonstrated a potent GIPR agonist activity with an EC50 of just 1 pM in human GIPR-mediated cAMP activation assays. Conversely, the competitive treatment tirzepatide showed an EC50 of 3 pM, suggesting that ASC48 could potentially offer higher efficacy as a GIPR agonist, supporting its further development for clinical trials.

Ascletis’ Commitment to Innovation


Ascletis employs an innovative approach to drug discovery focusing on metabolic diseases such as obesity and diabetes. The company has built an extensive pipeline, including various candidates for oral small molecules and peptide therapies that target essential pathways like GLP-1, GIPR, and GCGR. Their lead program, ASC30, is currently undergoing evaluation in two global Phase III studies aimed at obesity treatment, highlighting Ascletis’ commitment to bringing effective therapeutics to market.

Insights and Future Directions


Ascletis intends to push forward with clinical evaluations based on the promising data garnered from their preclinical studies. With the potential to reshape obesity treatment paradigms, these new therapies could offer hope to both patients and healthcare providers dealing with the growing obesity epidemic.

Further investigations and clinical trials will confirm the findings and set the stage for a broader application of these innovative treatments. Together, these studies reinforce Ascletis' position as a front-runner in developing game-changing therapies in weight management and metabolic disease.

For those interested in learning more about Ascletis Pharma and its pipeline, further details are available through their official website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.